编号：2026-005 | √特定对象调研 | | □分析师会议 | | --- | --- | --- | | 投资者关系活动类 □媒体采访 | | □业绩说明会 | | 别 □新闻发布会 | | □路演活动 | | □现场参观 | √其他：电话会议 | | | 参与单位名称及人 | 长城基金：吴驰；广发证券：谢璐、陈琳云；中邮证券：赵洋。 | | | 员姓名 | | | | 时间 2026 年 3 | 月 2 日 | | | 地点 公司 | | | | 上市公司接待人员 | 谭梅、章佳佳、陈银琼 | | | 姓名 | | | | | 1、请问目前塑料管道行业的竞争格局如何？ | | | | 答：近几年来，市场需求疲弱，行业竞争加剧，中小型企业生存困难甚至加速 | | | | 淘汰，行业集中度进一步提升，品牌企业之间的竞争加剧。 | | | | 2、新的一年，公司计划如何做好零售和工程业务的拓展？ | | | | 答：公司零售业务积极做大做强，全力做好市场份额和户均额的提升；工程业 | | | | 务则更强调风险控制，转型提质，实现高质量发展。 | | | | 3、请问公司当前的市场需求情况？ | | | ...

摘要 防水产品涨价交流 20260302 下难度较大。 近三年行业涨价函的发布与落地节奏如何，价格最终通常如何演变？ 近三年整体呈现较为稳定的"循环"特征：开年或年底通常会出现涨价预期/通 知，实际执行主要集中在 3 月 15 号之前完成预热沟通与提价推进；3 月 15 号 到 6 月中旬左右往往是相对容易推动价格上移的窗口期，原因在于客户在获取 价格与授信政策后，通常会在一定程度上接受部分调价。随后若年内销量与需 求预期偏弱，价格端可能通过特批等方式出现回落；下半年往往趋于执行相对 持平的价格政策。品类差异上，非大宗、使用占比较特殊或不常用的产品提价 后相对不易快速回落；而热熔类防水卷材、SBS、APP、自粘类卷材及防水涂 料等使用量大、价格敏感度高的大宗品种，价格波动更为频繁且更易受竞争影 响。 预计"涨 5%以内"的判断口径是什么？涨价通常只覆盖新订单还是也会影响 存量项目？ 防水材料行业计划在 3 月 1 日至 15 日与客户沟通提价，目标幅度为 5%-10%，但考虑到市场环境，实际落地 5%以内较为可行。历史数据 显示，年初或年底常有涨价预期，3 月中旬至 6 月中旬是提价窗口期， 下半年价格趋于稳 ...

Overview - The demand for caprolactam (CPL) is resilient in key downstream applications such as nylon 6, textiles, packaging films, automotive lightweighting, and electronics, leading to continuous growth in the caprolactam market. By 2025, China's caprolactam demand is projected to reach 6.817 million tons, a year-on-year increase of 5.1% [1] - To match the growing market demand, domestic caprolactam producers are expanding their capacities. However, due to previous rapid capacity expansions, the industry is currently in a state of oversupply, with production capacity expected to reach 8.07 million tons by 2025, a year-on-year increase of 16.1% [1] Market Policies - Caprolactam is classified as a hazardous chemical, and its production, storage, transportation, and usage are strictly regulated in China. Recent policies have been implemented to ensure safety and promote the industry's development towards scale, intensification, and greenness [5] Industry Chain - The upstream of the caprolactam industry includes suppliers of raw materials such as benzene, ammonia, hydrogen peroxide, sulfuric acid, and cyclohexanone. The midstream involves the production and purification of caprolactam, while the downstream market encompasses applications in nylon 6, pharmaceutical intermediates, polyurethanes, and specialty chemicals [6] Demand Structure - Currently, 95% of caprolactam is used to produce nylon 6 (PA6), which is further processed into nylon fibers, engineering plastics, and films. Nylon fibers account for over 60% of PA6 consumption, primarily used in textiles and industrial applications. The demand structure and application scenarios directly influence the market demand for caprolactam [7] Development Status - The demand for high-quality, differentiated nylon 6 continues to rise, driven by various sectors. By 2025, the caprolactam production is expected to reach 6.85 million tons, with exports projected at 167,600 tons, generating approximately $19.2 million in export revenue [8] Competitive Landscape - The caprolactam industry is experiencing a consolidation trend, with larger enterprises capturing a significant market share. By 2025, 80% of the industry capacity will be held by companies with capacities of 400,000 tons or more, with the top five companies accounting for 48% of the market [9] - Key players include Fujian Yongrong Holdings Group, which has established a comprehensive supply chain from benzene to nylon fibers, and Luxi Chemical Group, which has diversified its product offerings and focuses on innovation [10] Development Trends - The industry is expected to shift towards concentration and integration, with leading companies dominating the market. The focus will be on green and low-carbon production, driven by stringent environmental regulations [11][12] - Companies will enhance their global presence and supply chain resilience, leveraging technological advantages to expand into emerging markets and optimize their supply chain strategies [13]

Core Insights - The recent policy initiatives from nine government departments aim to promote high-quality development in the pharmaceutical retail industry, focusing on industry integration, prescription outflow, and commercial insurance [1][2][3] - The pharmaceutical retail market in China is expected to grow from CNY 2.41 trillion in 2020 to CNY 2.95 trillion by 2024, representing a 22.4% increase [2] - The industry is transitioning from traditional drug sales to comprehensive health services, enhancing community health support and resilience in the health security system [2][3] Industry Transformation - The policy encourages horizontal mergers and acquisitions among retail pharmaceutical companies to enhance efficiency and service quality [3][5] - Local governments are optimizing the business environment for retail pharmacies, including streamlining the application process for drug operation licenses [1] - Jiangxi Province has reported an increase in the retail pharmacy chain rate from 50.2% in 2024 to 60.3% in 2025, surpassing the national average [1] Company Responses - Yao Yi Tang is committed to responding to the new policies by enhancing its community health service capabilities and improving consumer access to quality healthcare [3] - Lao Bai Xing is exploring merger and acquisition opportunities while maintaining communication with potential targets to strengthen its alliance business [3] Industry Leaders' Benefits - The policy is expected to provide long-term benefits to leading retail pharmacies, enhancing their ability to manage outpatient prescriptions and increasing their market position [5][6] - The industry is entering a critical phase of structural transformation, characterized by store closures, increased concentration, and a restructured profit model [4][6] - The focus on diverse services such as chronic disease management and medication guidance will create a new profit ecosystem combining drugs, medical devices, and health management [4]

Core Insights - The poultry vaccine industry is crucial for preventing infectious diseases in poultry and is the foundation of modern poultry farming disease control [1] - China, as a major poultry producer and consumer, has a stable poultry production growth, which provides a solid demand base for the poultry vaccine market [1][8] - The market for poultry vaccines is expected to expand due to increased investment in disease prevention and a shift towards precision immunization models [1][9] Industry Overview - Poultry vaccines are biological agents developed specifically for birds such as chickens, ducks, and turkeys, aimed at inducing specific immune responses to prevent or control infectious diseases [2][3] - The poultry vaccine market can be categorized based on technology, pathogen type, usage characteristics, and vaccination methods [3][4] Market Dynamics - The Chinese poultry vaccine industry has a complete and interconnected supply chain, with high technical barriers in R&D and core raw material supply [5][6] - The demand is driven by government procurement of high-pathogenic avian influenza vaccines and market purchases from large farming groups and small farms [6][8] Policy Environment - The Chinese government has implemented strict management regulations to ensure the quality of veterinary biological products, including several guidelines and policies from 2022 to 2025 [6][7] - The mandatory immunization policy for major diseases has stabilized the vaccine coverage rate at over 98.7%, reinforcing the foundation for disease control in poultry [8] Market Growth Projections - The poultry meat production in China is projected to grow from 23.61 million tons in 2020 to 28.37 million tons by 2025, with a compound annual growth rate of 3.74% [9] - The poultry vaccine market is expected to recover and grow to 69.5 billion yuan in 2024, driven by increasing poultry output and vaccination demand [11][12] Vaccine Segmentation - The poultry vaccine market is primarily composed of inactivated vaccines, live vaccines, and other types, with inactivated vaccines holding over 65% market share [12] - The market for inactivated vaccines is projected to reach 4.65 billion yuan in 2024, while the segment for other vaccines, including genetically engineered and multivalent vaccines, is expected to grow significantly [12] Future Trends - The poultry vaccine industry is anticipated to achieve high-quality development driven by technological innovation, market consolidation, and demand upgrades [13] - Multi-valent vaccines will become the main focus of research and development, with new technologies like mRNA and viral vector vaccines accelerating commercialization [14] - The industry is expected to transition from a single vaccine supply model to a comprehensive service model that includes vaccines, diagnostics, and customized immunization plans [16]

2026-02-12 摘要 VLOC 即期运价维持高位，一年期租金大幅上涨，反映船东对 2026 年 市场乐观预期。地缘政治风险，如美伊关系紧张，可能导致运价短期内 突破 15-20 万美元，长期僵持或制裁将稳步推升运价。 俄乌冲突加剧欧盟对俄海运禁令，增加俄油影子船队运营难度，收缩合 规船队运力，利好阿芙拉型和苏伊士型油轮市场，运价有望进一步上行。 印度在美国压力下减少俄罗斯原油进口，转向美国和委内瑞拉，提升合 规远洋运输需求。12 月印度从俄罗斯进口原油量减少，未来或逐步转向 合规市场。 影子船队面临生存空间缩小、运营难度加大的挑战，受制裁邮轮承担全 球原油出口的重要比例，但高昂的维修费用和扣船风险使其运营风险增 加。 人民币国际化进程加速，沙特阿美对华原油出口人民币结算比例已达 45%，中俄本币结算比例超 90%，推动大宗商品人民币结算，或将挑 战美元主导地位。 Q&A 目前游轮行业的市场状况如何？ 油轮跟踪：美伊局势僵持，行业供给脆弱 20260212 游轮行业当前处于一个非常高景气的状态，未来发展有可能大概率超过此前预 期。近期发生了两个重要变化：地缘局势的升级和行业集中度的大幅提升，这 些因素将显 ...

Core Insights - The number of private equity firms with over 10 billion yuan in assets has reached a historical high of 122 as of the end of January, an increase of 10 from the end of last year [1][5] - Among these, 8 firms have crossed the 10 billion yuan mark for the first time, including Sichuan Development Securities Investment, which is a state-owned enterprise [1][5] - The performance of these firms has been strong, with an overall return of 6.41% in January, and 97.5% of the firms reporting positive returns [2][6] Group 1: Private Equity Growth - The number of private equity firms with over 10 billion yuan has increased to 122, marking a historical high [1][5] - Eight firms have newly crossed the 10 billion yuan threshold, while five have returned to this category [1][5] - Sichuan Development Securities Investment is highlighted as a significant state-owned firm achieving this milestone [1][5] Group 2: Performance Metrics - As of the end of January, 80 firms reported an overall return of 6.41%, with 78 firms achieving positive returns [2][6] - Among the positive performers, 28 firms had returns within 5%, 41 firms between 5% and 9.99%, and 9 firms exceeded 10% [2][6] - Notable firms with outstanding performance include Jiuqi Investment, Hainan Xiwa, and Qianyi Investment [2][6] Group 3: Market Dynamics - The increase in the number of billion-yuan private equity firms is attributed to a recovering market environment, improved fundraising efficiency, and the maturation of investment strategies [3][7] - The concentration of capital in top-performing firms is accelerating, indicating a "Matthew Effect" where funds are increasingly directed towards firms with stable performance and strong branding [3][7] - The return of funds from banks and securities firms has also contributed to the growth in private equity assets [3][7]

Investment Rating - The report maintains a "Buy" rating for the company [13] Core Viewpoints - Aima Technology, as a leader in the electric two-wheeler industry, has a solid foundation and a clear growth path. The industry is in a mature stage dominated by replacement demand, with increasing market concentration due to new national standards raising compliance and technical barriers [4][11] - The company is actively cultivating two new growth curves: electric tricycles and overseas markets, leveraging its brand and channel advantages to increase market share [4][9] Industry Demand Trends and Competitive Advantages - The demand side is driven by replacement and structural upgrades. The domestic electric two-wheeler ownership is at a high level, with replacement demand becoming the main source of consumption. The market is entering a stable development phase [8][29] - The competitive landscape shows a clear trend towards concentration, with the "dual oligopoly" structure solidifying. The new national standards are expected to accelerate the exit of tail brands, releasing market share for leading companies [8][39] Future Growth Potential - The company is focusing on the electric tricycle market, which has high growth and profitability potential. The domestic market is fragmented, and Aima is expected to continue increasing its share [9][10] - In overseas markets, particularly Southeast Asia, there is significant growth potential due to low electric penetration rates and supportive policies [9][10] Asset Quality and Shareholder Returns - The company has a healthy asset structure with high cash reserves and low interest-bearing debt. As of Q3 2025, cash assets accounted for a significant portion of total assets, and the company has a low interest-bearing debt ratio of 6.87% [10][22] - The company has increased its cash dividend payout ratio to 45% in the first half of 2025, indicating a commitment to shareholder returns [10][22] Investment Recommendations - The company's main business is solid, and it is expected to strengthen its leading position in the industry. The report forecasts net profits of 2.294 billion, 2.568 billion, and 2.921 billion yuan for 2025-2027, with corresponding P/E ratios of 11.44, 10.22, and 8.99 times, respectively [11]

Core Viewpoint - The electric light transportation market is experiencing significant growth, with companies like Tailg Technology preparing for IPOs to capitalize on this trend. Tailg Technology is positioned as the third-largest electric two-wheeler manufacturer in China, with a projected revenue of 13.6 billion RMB in 2024 [2][7]. Industry Overview - The electric light transportation tools market includes electric two-wheelers, electric three-wheelers, and other light electric vehicles, with electric two-wheelers being the largest segment globally due to performance improvements and supportive green policies [4]. - The supply chain consists of upstream material suppliers, midstream manufacturers, and downstream sales and after-sales services, with intense competition leading to a concentration of market share among leading companies [6][26]. Company Positioning - Tailg Technology holds a 5.2% market share in the global electric light transportation market and a 12.7% share in the Chinese electric two-wheeler market, making it the third-largest player in both segments [6][7]. - The company operates six production bases in mainland China and one overseas in Vietnam, with a significant reliance on a network of over 5,597 domestic and 412 overseas dealers for sales [10][11]. Financial Performance - Tailg Technology's revenue is primarily driven by electric bicycles, which contribute over 50% of total income, while electric motorcycles and batteries each account for around 20% [14][17]. - The company has seen a rise in average selling prices for its products, with electric bicycles increasing from 1,297.2 RMB to 1,393.7 RMB and electric motorcycles from 1,468.7 RMB to 1,585.3 RMB between 2023 and 2025 [14][17]. - Projected revenues for 2023, 2024, and the first nine months of 2025 are approximately 11.88 billion RMB, 13.6 billion RMB, and 14.84 billion RMB, respectively, with corresponding net profits of about 286 million RMB, 472 million RMB, and 823 million RMB [17]. Market Trends - The global electric light transportation market is expected to grow from 263.2 billion RMB in 2024 to 505.9 billion RMB by 2029, with a compound annual growth rate (CAGR) of approximately 11.7% [17]. - The Chinese electric two-wheeler market is projected to reach 57.3 million units in 2024, with an expected CAGR of 6.2% from 2025 to 2029 [21]. - Chinese brands are increasingly shifting from product exports to brand-led overseas expansion, with market share in the overseas electric two-wheeler market expected to rise from 15.1% in 2024 to 20.8% by 2029 [21]. IPO Plans - Tailg Technology plans to use the funds raised from its IPO to enhance production capacity, expand sales networks, invest in research and development, and improve brand recognition through marketing efforts [25].

Core Viewpoint - The stock of *ST WanFang has experienced a significant decline, with 15 consecutive trading days of price drops, primarily due to deteriorating fundamentals and a warning of potential delisting [3][4]. Group 1: Company Performance - On January 13, *ST WanFang announced a projected revenue of less than 300 million yuan for 2025, with both net profits before and after non-recurring items expected to be negative, triggering delisting risks under Shenzhen Stock Exchange rules [3]. - The stock price fell to 2.33 yuan, marking a new low since April 15, 2004, following a series of 14 consecutive daily limit-downs [3]. - The company, originally named ZhongLiao International, was established in May 1993 and listed in November 1996, but faced continuous losses shortly after its IPO, leading to a suspension in 2004 [3]. Group 2: Industry Implications - The decline of *ST WanFang highlights a broader trend of underperforming stocks facing delisting as the annual report season begins, emphasizing the importance of avoiding fundamental risks in investments [4]. - The potential exit of *ST WanFang from the market could lead to increased concentration in the agriculture sector, presenting opportunities for investors to identify long-term growth potential in the industry [4].